ALK acquires drug against swimmer's ear from now former US partner
Allergy firm ALK is now the sole owner of a drug against swimmer's ear after the company offered an undisclosed sum to US biotech and pharmaceutical Otonomy, which developed the drug and until now was in a partnership with ALK since June last year.
.jpg)
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CHRISTOFFER ØSTERGAARD
Allergy company ALK is now the exclusive owner of the FDA-approved drug Otiprio, used for treating acute otitis media, also known as swimmer's ear, of which there are more than 4 million cases annually in the US spread out among 3.4 million patients.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK expands digital venture with US partnership
For subscribers
.jpg)
ALK increases sales in Q2, but operating result decreases
For subscribers
.jpg&w=384&q=75)
